Ignite Creation Date:
2024-05-06 @ 7:53 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06178770
Status:
COMPLETED
Last Update Posted:
2023-12-21
First Post:
2023-12-12
Brief Title:
Injection Intervals in Real-world Neovascular Age-related Macular Degeneration nAMD Patients Switching to Brolucizumab With at Least 12 Months of Follow-up
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Key Dates - Follows AllAPIJSON File Order
Start Date:
2021-12-01
Start Date Type:
ACTUAL
Primary Completion Date:
2022-12-12
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-12-12
Completion Date Type:
ACTUAL
First Submit Date:
2023-12-12
First Submit QC Date:
December 12 2023
Study First Post Date:
2023-12-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-12
Last Update Post Date:
2023-12-21
Last Update Post Date Type:
ACTUAL